ObsEva
ObsEva is a clinical-stage biopharmaceutical company developing therapeutics for women's reproductive medicine, with focus on endometriosis, headquartered in Geneva, Switzerland and publicly traded on NASDAQ as OBSV.
- Company typePublic
- Founded2012
- HeadquartersPlan-les-ouates, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ObsEva does
ObsEva is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for women's reproductive medicine, with emphasis on endometriosis and related indications. Founded in 2012 and headquartered in Plan-les-Ouates (Geneva), Switzerland, the company is publicly traded on NASDAQ under the ticker OBSV and operates with a headcount of 11-50 employees. No specific named products, pipeline candidates, or therapeutic assets were disclosed in the available source material, and the company has not disclosed commercial revenue, customers, or distribution channels.
The company has historically funded its operations through multiple venture and debt financing rounds between 2013 and 2019, totaling approximately $228M, with investors including New Enterprise Associates, Sofinnova Partners, Novo Holdings, OrbiMed, and Oxford Finance LLC. The leadership team includes co-founders Ernest Loumaye (co-founder & CEO) and André Chollet (co-founder & CSO), alongside Elizabeth Garner MD MPH (Chief Medical Officer), Jean-Pierre Gotteland (Chief Scientific Officer and Head of R&D), Brandi Howard (CCO), and Luigi Marro (Chief Transformation Officer). Reported financials show a net loss of -$58.38M, consistent with pre-commercial clinical-stage burn. No AI/ML capabilities, technology platform details, patents, or marketing/distribution channels were disclosed in the source data.
ObsEva firmographics
Firmographics- Name
- ObsEva
- Website
- https://obseva.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ObsEva is a clinical-stage biopharmaceutical company developing therapeutics for women's reproductive medicine, with focus on endometriosis, headquartered in Geneva, Switzerland and publicly traded on NASDAQ as OBSV.
- Ownership category
- akta.pro rank
ObsEva industry classification
Industry- Product category
- Women's Health Pharmaceuticals
- akta.pro primary industry
- Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)
- akta.pro secondary industry
- Sexual & Reproductive Health (STI Care, Vulvovaginal Disorders) (HLAKAJAJ)
Keywords
Where ObsEva is headquartered
LocationHeadquarters
- HQ city
- Plan-les-ouates
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
ObsEva business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
ObsEva product offering
Product offeringCore offering
ObsEva is a clinical-stage specialty biopharmaceutical company that discovers and develops novel therapeutics for women's reproductive medicine, with a primary focus on treatments for endometriosis and related indications. The company operates from Geneva, Switzerland, is publicly listed on NASDAQ (OBSV), and is pre-commercial, with no approved or revenue-generating products identified in the available source material.
Product overview
ObsEva is a clinical-stage biopharmaceutical company focused on developing treatments for women's reproductive health conditions. The company is based in Geneva, Switzerland, and trades on NASDAQ under the symbol OBSV. No specific named products, pipeline candidates, or therapeutic candidates were identified in the provided source material.
Differentiator
Problem solved
Functional benefit
Companies that use ObsEva
Customer profileSegments1 record
Ideal customer profiles1 record
ObsEva technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ObsEva partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights3 records
ObsEva competitors and assessment
Company assessmentDirect peers
- TherapeuticsMD: Women's health specialty pharmaceutical company focused on reproductive health and menopause-related therapies. Comparable in patient population, commercial model, and clinical-development profile.
- Myovant Sciences (now Sumitomo Pharma): Clinical-to-commercial biopharma historically focused on women's health and endocrine conditions, including endometriosis therapies (Myfembree/relugolix). Directly comparable in therapeutic focus, clinical-stage origin, and women's reproductive medicine pipeline.
Broad incumbents
- AbbVie: Global biopharma with Orilissa/Lupron for endometriosis and a major women's health franchise. Competes head-to-head with ObsEva in endometriosis and sets the commercial benchmark.
- Organon & Co. Large women's-health-focused specialty pharma spun out of Merck, with a portfolio spanning fertility, contraception, and reproductive medicine. Comparable as a major incumbent in the same end markets ObsEva targets.
- Ferring Pharmaceuticals: Private specialty pharma with deep reproductive medicine and IVF portfolio (e.g., Menopur, Bravelle). Comparable as an incumbent in reproductive endocrinology and fertility treatments.
- Merck KGaA (Life Science / Healthcare): Operates Gonal-f and other leading fertility treatments globally. Comparable as an established incumbent in the reproductive endocrinology and fertility space ObsEva targets.
Emerging players
- Agile Therapeutics: Women's health specialty pharma focused on prescription contraceptives. Comparable in indication overlap (contraception/reproductive medicine) and small-cap clinical/commercial profile.
- Evofem Biosciences: Women's sexual and reproductive health company commercializing Phexxi for contraception and STI prevention. Comparable in therapeutic focus on reproductive medicine and similar small-cap commercial-stage profile.
- Daré Bioscience: Clinical-stage women's health biopharma developing novel therapies in contraception, reproductive health, and menopause. Comparable as a small-cap, clinical-stage women's reproductive health peer.
Regional players
- Gedeon Richter: European-headquartered specialty pharma with a significant women's health and reproductive medicine portfolio. Comparable as a regional incumbent in the same therapeutic categories.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
ObsEva social profiles
Digital presenceObsEva financial estimates
Financial estimateRevenue estimate
Valuation estimate
ObsEva leadership team
Management profileNumber of profiles
Profiles8 records
ObsEva funding detail
Funding detailFunding overview
Funding rounds5 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ObsEva M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ObsEva
What does ObsEva do?
ObsEva is a clinical-stage specialty biopharmaceutical company that discovers and develops novel therapeutics for women's reproductive medicine, with a primary focus on treatments for endometriosis and related indications. The company operates from Geneva, Switzerland, is publicly listed on NASDAQ (OBSV), and is pre-commercial, with no approved or revenue-generating products identified in the available source material.
Is ObsEva a public or private company?
ObsEva is a public company. It is classified as public and is currently operating.
When was ObsEva founded?
ObsEva was founded in 2012. It employs 11 to 50 people.
Where is ObsEva based?
ObsEva is headquartered in Plan-les-ouates, Switzerland, in the Europe region.
Who are ObsEva's main competitors?
Direct peers on record are TherapeuticsMD and Myovant Sciences (now Sumitomo Pharma). Broad incumbents are AbbVie, Organon & Co., Ferring Pharmaceuticals and Merck KGaA (Life Science / Healthcare). Emerging players are Agile Therapeutics, Evofem Biosciences and Daré Bioscience. Gedeon Richter is listed as a regional player.
Does ObsEva have an API?
No public API is recorded for ObsEva.
What industry is ObsEva in?
ObsEva's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility), with a secondary code of HLAKAJAJ, Sexual & Reproductive Health (STI Care, Vulvovaginal Disorders).